Cambridge Healthtech Institute’s 11th Annual

Kinase Inhibitor Discovery
( 激酶抑制剂的新药发现 )


The human kinome is a very large and druggable class of targets with many disease indications. Because of this, the kinome targets account for a significant portion of drug discovery efforts. Kinase inhibitor discovery is a very active area as developers are exploring more deeply into designing immune-modulatory agents as single or combination therapies, tackling chronic disease indications such as inflammation and CNS disorders, as well as effectively harnessing allosteric modulators, and covalently binding compounds. Cambridge Healthtech Institute’s 11th Annual Kinase Inhibitor Discovery conference will gather academic and industry leaders to collaborate and discuss advances in kinase drug discovery.


Who should attend: PRESIDENTS, VICE PRESIDENTS, CEOs, CTOs, MEDICINAL CHEMISTS and SCIENTISTS working in drug development from academia, government, or industry


Coverage will include, but is not limited to:

  • Tryosine kinase inhibitors
  • Covalent kinase inhibitors
  • Target covalent inhibitors
  • Macrocycle inhibitors
  • Reversible inhibitors
  • Fragment and structure-based design
  • Lead & target optimization
  • AK, MAPK, P13K and other kinases

* 活动内容有可能不事先告知作更动及调整。

Choose your language